Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen

NCT00615056 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00615056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
April 30, 2012
Enrollment
171 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms